Xeris Biopharma Holdings, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-06-30. Between them they name 2 people, with 2 appointments and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Nerissa Kreher, effective 2026-07-01
On June 29, 2026, the Board of Directors (the "Board") of Xeris Biopharma Holdings, Inc. (the "Company") increased the size of the Board from seven (7) to eight (8) members, thereby creating a vacancy on the Board, and appointed Nerissa Kreher, M.D., to fill such vacancy, effective as of July 1, 2026.
Appointed: Nerissa Kreher, Director
Dr. Kreher will serve as a Class III director and her term will expire at the Company's 2027 annual meeting of stockholders, or until her earlier death, resignation, or removal.
Departing: Jeffrey Sherman, Director
On April 20, 2026, Dr. Jeffrey Sherman, a member of the Board of Directors (the "Board") of Xeris Biopharma Holdings, Inc. (the "Company"), provided notice to the Company of his decision to retire from the Board and not stand for reelection at the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting").
Find people with the same kind of experience as the Director at Xeris Biopharma Holdings, Inc., with the record behind each one.
Find candidates like Director at Xeris Biopharma Holdings, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Xeris Biopharma Holdings, Inc. is in the news or changes leadership.
Get an alert when Xeris Biopharma Holdings, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Xeris Biopharma Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.